Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind and Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Moderate to Severe Atopic Dermatitis

NCT04162899 is registered in ClinicalTrials.gov with Reistone Biopharma Company Limited as lead sponsor.

NCT NCT04162899
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04162899 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind and Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Moderate to Severe Atopic Dermatitis
Lead sponsor
Reistone Biopharma Company Limited
Phase
Phase 2
Overall status
Completed
Start date
November 6, 2019
Completion date
August 31, 2020
Enrollment
105 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis